摘要
目的 探讨孟鲁司特联合匹多莫德对儿童支气管哮喘患儿的疗效及肺功能的影响.方法 选取2012年12月～2013年12月我院收治的支气管哮喘患儿100例,全部患者随机分为观察组和对照组各50例,对照组口服孟鲁司特片5 mg,每晚1次.观察组同时口服匹多莫德口服液10mL,每日1次,疗程6个月.比较两组治疗后的临床疗效、治疗前后的日间和夜间咳嗽症状评分、咳嗽/肺部哮鸣音消失时间、住院时间及肺功能指标FEV1、FEV1/FVC、FEV1占预计值的变化情况.结果 观察组的疗效显著优于对照组（P＜0.05）.观察组日间和夜间咳嗽症状评分均较治疗前及对照组明显降低（P＜0.05）.观察组咳嗽/肺部哮鸣音消失时间、住院时间均较对照组短（P＜0.05）.观察组肺功能指标FEV1、FEV1/FVC、FEV1占预计值均较治疗前及对照组明显改善（P＜0.05）.结论 孟鲁司特联合匹多莫德对支气管哮喘患儿的疗效确切,明显改善患儿的临床症状和肺功能,缩短住院时间,值得广泛推广和应用.
Objective To investigate the combined effects of montelukast for children pidotimod efficacy in children with asthma and pulmonary function. Methods December 2012 to December 2013 in our hospital for children 100 patients with bronchial asthma. All patients were randomly divided into observation group and control group, 50 patients in the control group were given montelukast tablets,5mg orally every night. Observation group were added pidotimod, 10mL orally,once dally for 6 months, compare clinical efficacy after treatment of two groups before and after treatment in children with daytime and nighttime cough symptom scores, as well as cough/wheezing lungs disappeared/hospitalization time, and lung function FEV1,FEV1/FVC,FEVI% predicted changes. Results The efficacy of observation group was significantly better than the control group （P 〈0.05）. Daytime and nighttime cough symptom scores of observation group were significantly lower than before treatment and control group （P 〈0.05）. Coughing, wheezing lungs disappeared time of observation group was shorter than that of control group. Lung function FEVI, FEV1/FVC, FEVI% predicted values improved significantly than before treatment and control group （P 〈0.05）. Conclusion The efficacy of montelukast combined with pidotimod in treatment of children with bronchial asthma is exact, can significantly improve the clinical symptoms in children, improve lung function in children with asthma, shorten hospital stay, should be popularized and applied.
出处
《中国现代医生》
2014年第19期32-34,38,共4页
China Modern Doctor
基金
浙江省医药卫生科技计划(2011RCB036)
